References
- 1. World Health Organization, Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed June 1, 2020.
- 2. Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020; 30:367-69. DOI: 10.1038/s41422-020-0327-410.1038/s41422-020-0327-4
- 3. Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. Clin Chem Lab Med. 2020; 58(7):1100-05. DOI: 10.1515/cclm-2020-045910.1515/cclm-2020-0459
- 4. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clin Infect Dis. 2020;19;71(16):2079-88. DOI: 10.1093/cid/ciaa53810.1093/cid/ciaa538
- 5. Tian W, Jiang W, Yao Y, Nicholson CJ, Li RH, Sigurslide HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875-83. DOI: 10.1002/jmv.2605010.1002/jmv.26050
- 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. DOI: 10.1016/S0140-6736(20)30566-310.1016/S0140-6736(20)30566-3
- 7. Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020;100(6):794-800. DOI: 10.1038/s41374-020-0431-610.1038/s41374-020-0431-6718482032341519
- 8. Henry BM, De Olivera MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune bio-marker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-28. DOI: 10.1515/cclm-2020-036910.1515/cclm-2020-036932286245
- 9. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Cicarelli M, et al. Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. J Clin Med. 2020;9(5):e1548. DOI: 10.3390/jcm905154810.3390/jcm9051548729083332443899
- 10. Health Ministry of Spain, Covid-19 situation in Spain. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/situacionActual.htm. Accessed July 14, 2020.
- 11. Metropolitan Area of Barcelona, Metropolitan Barcelona information on COVID-19. Available from: http://www.amb.cat/es/web/area-metropolitana/covid19. Accessed July 14, 2020.
- 12. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-34. DOI: 10.1515/cclm-2020-019810.1515/cclm-2020-019832119647
- 13. Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun. 2020. DOI: 10.1016/j.jaut.2020.10247310.1016/j.jaut.2020.102473718037632439209
- 14. Julián-Jimenez A, González del Castillo J, Candel F. Usefulness and prognostic value of biomarkers in patients with community-acquired pneumonia in the emergency department. Med Clin (Barc). 2017;148(11):501-10. DOI: 10.1016/j.medcle.2017.04.03310.1016/j.medcle.2017.04.033
- 15. Li X, Wang L, Yan S, Xiang L, Zhu J, Shen B, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128-32. DOI: 10.1016/j.ijid.2020.03.05310.1016/j.ijid.2020.03.053
- 16. Liu J, Liu S. The management of coronavirus disease 2019 (COVID-19). J Med Virol. 2020; 92(10):2146-51. DOI: 10.1002/jmv.2596510.1002/jmv.25965
- 17. Luo W, Lin Y, Yao X, Shi Y, Lu F, Wang Z, et al. Clinical findings of 35 cases with novel coronavirus pneumonia outside of Wuhan. Pulmonology. 2020. DOI: 10.21203/rs.3.rs-22554/v110.21203/rs.3.rs-22554/v1
- 18. Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. DOI: 10.1056/NEJMoa200203210.1056/NEJMoa2002032
- 19. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020;12(7):e12421. DOI: 10.15252/emmm.20201242110.15252/emmm.202012421
- 20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69. DOI: 10.1001/jama.2020.158510.1001/jama.2020.1585
- 21. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Clin Infect Dis. 2020;94:128-32. DOI: 10.1016/j.ijid.2020.03.05310.1016/j.ijid.2020.03.053
- 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI: 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5
- 23. Weiss P. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014-15. DOI: 10.1016/S0140-6736(20)30633-410.1016/S0140-6736(20)30633-4
- 24. Richardson S, Hirsch JS, Narasimhan M, Crawford J, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-59. DOI: 10.1001/jama.2020.677510.1001/jama.2020.6775717762932320003
- 25. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa27010.1093/cid/ciaa270718444432173725
- 26. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA. Intern Med 2020;1;180(8):1081-89. DOI: 10.1001/jamainternmed.2020.203310.1001/jamainternmed.2020.2033721867632396163
- 27. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020;12;71(6):1393-99. DOI: 10.1093/cid/ciaa41410.1093/cid/ciaa414718447332271369
- 28. Zhao Z, Chen A, Hou W, Graham JM, Li H, Rich-man PS, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS ONE. 2020;30;15(7):e0236618. DOI: 10.1371/journal. pone.0236618
- 29. Jean SS, Lee PI, Hsueh PRJ, et al. Treatment options for COVID-19: The reality and challenges. Microbiol Immunol Infect. 2020;53(3):436-43. DOI: 10.1016/j. jmii.2020.03.034
- 30. Grein J. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327-36. DOI: 10.1056/NEJMoa200701610.1056/NEJMoa2007016716947632275812
- 31. Liu YJ, Yang YL, Xu Y. What we learned from SARS may provide important insights into understanding and management of coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi. 2020;339-44.
- 32. Kerboua KE. NLR: A Cost-effective Nomo-gram to Guide Therapeutic Interventions in COVID-19. Immunol Invest. 2020;1:1-9. DOI: 10.1080/08820139.2020.177385010.1080/08820139.2020.177385032482134
- 33. McGonagle D, Sharif K, O’Regan A. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. DOI: 10.1016/j.autrev.2020.10253710.1016/j.autrev.2020.102537719500232251717
- 34. Moore JB and June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-74. DOI: 10.1126/science.abb892510.1126/science.abb892532303591
- 35. Qin C, Zhou L, Hu Z, Zhang S, Yang Y, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768. DOI: 10.1093/cid/ciaa24810.1093/cid/ciaa248710812532161940